131 related articles for article (PubMed ID: 21311094)
1. Could NSP5a3a be a target for head and neck cancer?
White MK; Khalili K
Oncotarget; 2010 Oct; 1(6):386. PubMed ID: 21311094
[No Abstract] [Full Text] [Related]
2. NSP 5a3a: a potential novel cancer target in head and neck carcinoma.
D'agostino L; Giordano A
Oncotarget; 2010 Oct; 1(6):423-435. PubMed ID: 21311098
[TBL] [Abstract][Full Text] [Related]
3. TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer.
Banerjee R; Russo N; Liu M; Basrur V; Bellile E; Palanisamy N; Scanlon CS; van Tubergen E; Inglehart RC; Metwally T; Mani RS; Yocum A; Nyati MK; Castilho RM; Varambally S; Chinnaiyan AM; D'Silva NJ
Nat Commun; 2014 Jul; 5():4527. PubMed ID: 25078033
[TBL] [Abstract][Full Text] [Related]
4. Ubiquitin-conjugating enzyme UBE2Q2 suppresses cell proliferation and is down-regulated in recurrent head and neck cancer.
Maeda H; Miyajima N; Kano S; Tsukiyama T; Okumura F; Fukuda S; Hatakeyama S
Mol Cancer Res; 2009 Sep; 7(9):1553-62. PubMed ID: 19723876
[TBL] [Abstract][Full Text] [Related]
5. Antisense inhibition of cyclin D1 in human head and neck squamous cell carcinoma.
Nakashima T; Clayman GL
Arch Otolaryngol Head Neck Surg; 2000 Aug; 126(8):957-61. PubMed ID: 10922227
[TBL] [Abstract][Full Text] [Related]
6. Proliferating cell nuclear antigen counts as markers of cell proliferation in head and neck cancer.
Lörz M; Meyer-Breiting E; Bettinger R
Eur Arch Otorhinolaryngol; 1994; 251(2):91-4. PubMed ID: 7517683
[TBL] [Abstract][Full Text] [Related]
7. Head and neck squamous cell carcinoma: mismatch repair immunohistochemistry and promoter hypermethylation of hMLH1 gene.
Tawfik HM; El-Maqsoud NM; Hak BH; El-Sherbiny YM
Am J Otolaryngol; 2011; 32(6):528-36. PubMed ID: 21353335
[TBL] [Abstract][Full Text] [Related]
8. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
9. Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells.
Liu J; Uematsu H; Tsuchida N; Ikeda MA
Mol Cancer; 2011 Jul; 10():95. PubMed ID: 21801448
[TBL] [Abstract][Full Text] [Related]
10. Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB.
Amin AR; Khuri FR; Chen ZG; Shin DM
Cancer Prev Res (Phila); 2009 Jun; 2(6):538-45. PubMed ID: 19470788
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic modifications control loss of adhesion and aggressiveness of cancer stem cells derived from head and neck squamous cell carcinoma with intrinsic resistance to cisplatin.
Milan TM; Eskenazi APE; Bighetti-Trevisan RL; de Almeida LO
Arch Oral Biol; 2022 Sep; 141():105468. PubMed ID: 35679799
[TBL] [Abstract][Full Text] [Related]
12. CK2 phosphorylates and inhibits TAp73 tumor suppressor function to promote expression of cancer stem cell genes and phenotype in head and neck cancer.
Lu H; Yan C; Quan XX; Yang X; Zhang J; Bian Y; Chen Z; Van Waes C
Neoplasia; 2014 Oct; 16(10):789-800. PubMed ID: 25379016
[TBL] [Abstract][Full Text] [Related]
13. [The Role of microRNA in head and neck cancer focusing on sinonasal carcinoma].
Kovaříková H; Chmelařová M; Palička V
Cas Lek Cesk; 2016; 155(2):45-50. PubMed ID: 27088793
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling.
Aggarwal S; Takada Y; Singh S; Myers JN; Aggarwal BB
Int J Cancer; 2004 Sep; 111(5):679-92. PubMed ID: 15252836
[TBL] [Abstract][Full Text] [Related]
15. Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy.
Lepikhova T; Karhemo PR; Louhimo R; Yadav B; Murumägi A; Kulesskiy E; Kivento M; Sihto H; Grénman R; Syrjänen SM; Kallioniemi O; Aittokallio T; Wennerberg K; Joensuu H; Monni O
Mol Cancer Ther; 2018 Sep; 17(9):2060-2071. PubMed ID: 29970484
[TBL] [Abstract][Full Text] [Related]
16. Cell-cycle gene expression analysis using real time PCR in locally advanced squamous-cell head and neck cancer.
Woźniak G; Herok R; Jaksik R; Misiołek M; Kolebacz B; Fiszer-Kierzkowska A; Miśkiewicz-Orczyk K; Szymczyk C; Maciejewski A; Głowacki G; Suwiński R
Adv Med Sci; 2016 Sep; 61(2):293-299. PubMed ID: 27136187
[TBL] [Abstract][Full Text] [Related]
17. Regulation of gene Expression by 1alpha,25-dihydroxyvitamin D3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma Cells.
Akutsu N; Lin R; Bastien Y; Bestawros A; Enepekides DJ; Black MJ; White JH
Mol Endocrinol; 2001 Jul; 15(7):1127-39. PubMed ID: 11435613
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
[TBL] [Abstract][Full Text] [Related]
19. mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma.
Schedel F; Pries R; Thode B; Wollmann B; Wulff S; Jocham D; Wollenberg B; Kausch I
Oncol Rep; 2011 Mar; 25(3):763-8. PubMed ID: 21240463
[TBL] [Abstract][Full Text] [Related]
20. Disruption of
Bui N; Huang JK; Bojorquez-Gomez A; Licon K; Sanchez KS; Tang SN; Beckett AN; Wang T; Zhang W; Shen JP; Kreisberg JF; Ideker T
Mol Cancer Ther; 2018 Jul; 17(7):1585-1594. PubMed ID: 29636367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
